Scott Mendel Elected to Quantum-Si Board of Directors
15 Mai 2023 - 2:00PM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced
the election of Scott Mendel, former President and Chief Executive
Officer of GenMark Diagnostics, Inc., to its Board of
Directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230515005191/en/
Scott Mendel Elected to Quantum-Si Board
of Directors (Photo: Business Wire)
Mr. Mendel has more than 30 years of financial and operational
leadership experience in the life sciences, diagnostics and
healthcare industries. Currently, he serves as a board member for
Visby Medical, Inc. and Akoya Biosciences, Inc. During his tenure
at GenMark, Mr. Mendel also served as Chief Operating Officer and
Chief Financial Officer, overseeing the Company’s growth to $200
million in annual sales, which led to its purchase by Roche
Diagnostics in 2021 for $1.8 billion. Previously, Mr. Mendel was
CFO at The Active Network and GE HealthCare.
“Scott’s election to our Board of Directors could not have come
at a more pivotal time as we charge ahead in expanding the
commercialization of our Platinum™ next-generation protein
sequencing system,” said Jeff Hawkins, CEO of Quantum-Si. “With his
exceptional business and financial acumen, we believe he will
fortify our team of advisors to enable our goal of providing every
researcher, scientist and clinician with a deeper understanding of
the role of proteins in cell biology and disease thereby advancing
human health.”
“By harnessing the power of its breakthrough technology and
innovation, Quantum-Si is poised to take remarkable leaps forward,
opening up new avenues for drug discovery and diagnostics,” said
Mr. Mendel. “I look forward to contributing my experience to
support Quantum-Si’s expansion as a leading player in the
proteomics landscape.”
Mr. Mendel received a Master of Business Administration from the
Kellogg School of Management at Northwestern University in Illinois
and a Bachelor of Science in finance from Indiana University
Bloomington.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at
quantum-si.com.
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as "expect," "estimate," "project," "budget," "forecast,"
"anticipate," "intend," "plan," "may," "will," "could," "should,"
"believes," "predicts," "potential," "continue," and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company's expectations with respect to future performance and
development and commercialization of products and services. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from those discussed in the forward-looking statements.
Most of these factors are outside the Company's control and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: the impact of COVID-19 on the
Company's business; the inability to maintain the listing of the
Company's Class A common stock on The Nasdaq Stock Market; the
ability to recognize the anticipated benefits of the business
combination, which may be affected by, among other things,
competition and the ability of the Company to grow and manage
growth profitably and retain its key employees; the Company's
ongoing leadership transition; changes in applicable laws or
regulations; the ability of the Company to raise financing in the
future; the success, cost and timing of the Company's product
development and commercialization activities; the commercialization
and adoption of the Company’s existing products and the success of
any product the Company may offer in the future; the potential
attributes and benefits of the Company’s commercialized PlatinumTM
protein sequencing instrument and the Company’s other products once
commercialized; the Company's ability to obtain and maintain
regulatory approval for its products, and any related restrictions
and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company's products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others the
Company's estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties
described under "Risk Factors" in the Company’s Annual Report for
the fiscal year ended December 31, 2022, and in the Company's other
filings with the SEC. The Company cautions that the foregoing list
of factors is not exclusive. The Company cautions readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230515005191/en/
Investor Contact Juan Avendano ir@quantum-si.com
Media Contact Anya Bolshem media@quantum-si.com
Quantum Si (NASDAQ:QSI)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Quantum Si (NASDAQ:QSI)
Historical Stock Chart
Von Mai 2023 bis Mai 2024